Secretion,blood levels and cutaneous expression of TL1A in psoriasis patients

TL1A is a TNF‐like cytokine which has been shown to co‐stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF‐α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti‐TNF‐α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large‐scale studies are warranted to investigate TL1A as a biomarker.     

Phenolic amides from <Emphasis Type="Italic">Tribulus terrestris</Emphasis> and their inhibitory effects on nitric oxide production in RAW 264.7 cells

A new phenolic amide, named cis-terrestriamide (7), together with ten known compounds (1–6, 8–11), were isolated from the methanolic extract of the fruits of Tribulus terrestris. The structure of 7 was elucidated on the basis of extensive analyses of 1D and 2D nuclear magnetic resonance spectroscopic and high resolution mass spectrometry data. Compounds 1, 2, 5, 6, 8, 9, and 11 exhibited inhibitory effects on the lipopolysaccharide-stimulated nitric oxide production in RAW 264.7 cells, with IC₅₀ values of 18.7–49.4 μM.     

Clinical significance of nutritional risk screening tool for hospitalised children with acute burn injuries: a cross‐sectional study

Background

We assessed the nutritional risks among children hospitalised with acute burn injuries and their associated clinical outcomes using three nutritional risk screening (NRS ) tools: Screening Tool for Risk of Impaired Nutritional Status and Growth (STRONG_KIDS ), Pediatric Yorkhill Malnutrition Score (PYMS ) and Screening Tool for the Assessment for Malnutrition in Pediatrics (STAMP ).

Methods

This prospective cross‐sectional study was conducted from October 2015 to November 2016, in a regional burn centre. Patients were screened by two independent observers, using the three NRS tools.

Results

A total of 100 children aged 3 months to 16.5 years were included. STRONG_KIDS identified 16% of patients as having high risk, with being identified 45% by PYMS and 44% by STAMP . After adjustment for confounding factors in multivariate regression analysis, patients in the high‐risk group had significantly longer median (SD) lengths of stay [medium versus high risk: STRONG_KIDS , 9.5 (6.6) versus 15.0 (24.2) days; PYMS , 8.5 (4.4) versus 13.0 (16.1) days; STAMP , 9.0 (5.7) versus 11.0 (17.4) days] and greater median (SD) weight loss [medium versus high risk: STRONG_{KIDS ,} 0.15 (0.8) versus ‐0.35 (0.8) kg; STAMP, 0.5 (0.7) versus 0 (0.1) kg] than patients in the medium‐risk group (P < 0.05). The strengths of agreement in the nutritional risk classification between the two observers were good (κ for STRONG_KIDS = 0.61; PYMS = 0.79; STAMP = 0.75) (P < 0.01).

Conclusions

The STRONG_KIDS , PYMS and STAMP tools could be useful and practical for determining which hospitalised children with acute burn injuries will need additional nutritional intervention.